RXi Pharmaceuticals, MirImmune deal

RXi granted MirImmune an exclusive license to use RNAi delivering technology, sd-rxRNA and rxRNAori, to develop cell-based cancer immunotherapies. MirImmune is responsible for R&D, manufacturing, regu...